A four-year-old London startup backed by Peter Thiel has raised a $55 million Series B round as it sets about “fixing the broken clinical trial industry.” The announcement comes as artificial intelligence is shaping up to revolutionize drug discovery and development.
Learn more about your ad choices. Visit podcastchoices.com/adchoices
Fler avsnitt av TechCrunch Industry News
Visa alla avsnitt av TechCrunch Industry NewsTechCrunch Industry News med TechCrunch finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
